Introduction {#sec1}
============

Asthma is one of the most common non-communicable respiratory disease, affecting about 6% of general population, that is currently more than 300 millions of people in the world[@bib1], [@bib2]; the trend of asthma prevalence seems to be at least stable,[@bib1] if not even increasing in the last few years.[@bib2], [@bib3] This epidemiological situation accounts for high and increasing health-related costs (direct and indirect),[@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9] particularly in those patients with suboptimal control of asthma.[@bib10], [@bib11]

Most of the patients with asthma achieve a good control of the disease using regularly low-to-medium doses of inhaled corticosteroids±other controllers, but a small proportion (accounting about 3.5--10% of all asthmatics[@bib12], [@bib13], [@bib14], [@bib15]) requires high dose of these drugs (and/or systemic corticosteroids) to be controlled or remains uncontrolled despite this therapy: these patients are defined as "severe asthmatics" according to the latest European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines.[@bib16] Severe asthma, although afflicting a minority of these patients, drives most costs of the disease.[@bib17]

Moreover, it is precisely the patients with more severe asthma (particularly if they have associated comorbidities and high peripheral eosinophils levels) who use systemic corticosteroids more frequently and at high dosages, with an increased risk of corticosteroid-related adverse events.[@bib18], [@bib19], [@bib20] Indeed, it is known that systemic corticosteroids are not without side effects, and that these are more frequent and severe in patients who use them continuously or frequently.[@bib21], [@bib22] The major adverse events related to the use of systemic corticosteroids (that are common to patients using high doses of inhaled corticosteroids for prolonged time[@bib23]) are: hypertension, osteoporosis and bone fracture, cataract and glaucoma, diabetes, respiratory infections, reduced growth velocity in children, and hypothalamic-pituitary-adrenal axis suppression.

Few studies analysed the impact, in terms of costs, of corticosteroid-related adverse events in several diseases, including asthma[@bib19], [@bib20], [@bib22], [@bib24], [@bib25], [@bib26], [@bib27]: the estimated annual cost in asthmatics ranges from about 600 Euros[@bib26] to about 5000 Euros in more severe patients.[@bib27]

The aim of this study is to create a pharmacoeconomic model to predict the costs of corticosteroid-related adverse events in severe asthmatics and applying it to the first published epidemiologic data from the Severe Asthma Network in Italy (SANI) registry.[@bib28], [@bib29]

Materials and methods {#sec2}
=====================

Study design {#sec2.1}
------------

A budget impact model (BIM) was developed to evaluate the pharmacoeconomic consequences of oral corticosteroid adverse events (OCS-AE) in adult patients with severe asthma. The analysis was conducted through a dynamic simulation model in Microsoft Excel® and carried out from the perspective of the Italian National Healthcare System (INHS). Our study initially provided a literature review aimed to identify data on:•asthma epidemiology•asthmatic comorbidities related to corticosteroids use•frequency of adverse events in severe asthma patients•adverse events cost

Model inputs included asthma epidemiology data, frequency of adverse events, percentage of severe asthma patients treated with OCS and adverse events cost. After identifying the study population and main OCS-related adverse events in adult\'s asthma patients, the economic impact of adverse events was estimated based on adverse events rate and events cost. Economic evaluation was conducted considering a main scenario, including all adverse events considered in a Sweeney\'s *et al* study that investigated the prevalence of systemic corticosteroid-induced morbidity in severe asthma using data from Optimum Patient Care Research Database (OPCRD) and British Thoracic Society (BTS) Difficult Asthma Registry.[@bib19] Specifically, we adopted prevalence data obtained from OPCRD database that included 7195 subjects in three age and gender matched groups: severe asthma (808), mild/moderate asthma (3975) and non-asthma controls (2412): patients with SA requiring regular OCS (GINA step 5) were compared with patients with mild/moderate asthma and non-asthmatic controls.

Adverse events evaluation was developed adopting Diagnosis-Related Group (DRG)-based national tariffs (diagnosis-related group tariffs system). In addition, an analysis subgroup, including some of most common OCS-related adverse events reported in available studies was considered: we researched cost of illness studies available in literature for Italy for diseases in analysis in order to use an alternative evaluation method, not related only to the acute event as it happens with the DRG system, and to observe their impact on the total. Based on different prevalence rates of morbidities associated with systemic steroid exposure provided by literature,[@bib19] we estimated costs per different patient groups: non-asthma controls, mild/moderate and severe asthmatics. Combining epidemiology data with frequency and OCS-related adverse events cost, we obtained budget impact analysis results. Final results report estimated direct cost per patient and total direct cost for overall target population, showing economic impact related to corticosteroid complications, potentially avoidable if these drugs were no longer administered.

Lastly, in order to assess the robustness of results, a deterministic sensibility analysis was developed changing main parameters used for the calculation (cost of adverse events and prevalence rates of OCS-related adverse events) by ±20%. In addition, for event costs we considered DRG costs related to Lombardy Region, as an alternative to national tariffs given the variability on the territory.

Study population {#sec2.2}
----------------

In order to obtain the target population, we started from national epidemiological data derived from Italian National Statistical Institute (ISTAT).[@bib30] As shown in [Table 1](#tbl1){ref-type="table"}, a 6.6% of asthma prevalence was applied to the total resident population in Italy, and 5% of asthmatics were considered to be affected by severe asthma (based on literature and expert opinion).[@bib3], [@bib28]Table 1Study population: demographic data input.Table 1Demographic dataItalian resident population (2017)60,589,445Asthma prevalence in Italy6.60%SA patients of total asthmatics5%SA patients treated with OCS62%

Finally, it was considered that 62% of patients with severe asthma were chronically treated with OCS, as emerged from the first extractions from SANI database (Severe Asthma Network in Italy).[@bib29]

Adverse events rate {#sec2.3}
-------------------

Rates of OCS-related adverse events were provided from an observational study published by Sweeney et al., [Table 2](#tbl2){ref-type="table"}. The study was based on Optimum Patient Care Research Database (UK setting) and compared patients with SA requiring regular OCS with patients with mild/moderate asthma and non-asthmatic controls (rhinitis diagnosis with no asthma diagnosis/asthma drugs and no exposure to OCS). The aim of Sweeney\'s study was to determine the prevalence of systemic corticosteroid-induced morbidity in severe asthma over 2-year analysis. Subjects (7195) had at least 2 years of continuous medical records and were aged \>12 years.Table 2Prevalence rates of potential systemic corticosteroid-induced comorbidity.Table 2ComorbidityPrevalence rates[a](#tbl2fna){ref-type="table-fn"}Non-astma controlsMild/moderate AsthmaSevere Asthma%%%Type II diabetes6%7%10%Obesity (BMI \>30)23%35%42%Osteopenia2%2%10%Osteoporosis3%4%16%Fracture4%3%5%Dyspeptic disorders24%34%65%Glaucoma3%3%4%Cataract4%5%9%Cardiovascular disease7%7%10%Hypertension25%29%34%Psychiatric disorders25%31%38%Hypercholesterolaemia11%14%15%Sleep disorder2%3%4%Chronic kidney disease7%9%14%[^2][^3]

Adverse events cost {#sec2.4}
-------------------

Economic evaluation of OCS-related adverse events was conducted by DRG Tariffs System, [Table 3](#tbl3){ref-type="table"}. This system classifies all patients in homogeneous groups according to resources absorption, allowing to economically quantify the use of resources and to provide an estimate of the cost per acute event from the INHS perspective.Table 3Asthma comorbidities: cost per event.Table 3ComorbidityEvent costType II diabetes€1391.49Obesity (BMI \>30)€1757.84Osteopenia€940.33Osteoporosis€1037.82Fracture€1984.96Dyspeptic disorders€958.51Glaucoma€1051.07Cataract€1051.07Cardiovascular disease€2096.82Hypertension€963.36Psychiatric disorders€1941.81Hypercholesterolaemia€428.43Sleep disorder€1408.88Chronic kidney disease€3734.46

Moreover, in order to extrapolate data cost from literature, we adopted results from cost of illness studies available for Italy to implement model subgroup analysis. We considered cost of the following illness: type 2 diabetes mellitus (T2DM), obesity, osteoporosis, glaucoma and chronic kidney disease, [Table 4](#tbl4){ref-type="table"}.[@bib31], [@bib32], [@bib33], [@bib34], [@bib35]Table 4Asthma comorbidities: cost of illness study results.Table 4ComorbidityCost of Illness (mean annual cost)Type II diabetes€ 2792Obesity€ 1166Osteoporosis€ 1325Glaucoma€ 734Chronic kidney disease€ 4508[^4][^5][^6][^7][^8]

Results {#sec3}
=======

Based on epidemiological data input, in Italy asthmatic subjects turned out to be about 3,999,600, of whom 199,980 with severe asthma. The number of patients with severe asthma OCS-treated was estimated to be 123,988 which represents the proportion of subjects potentially at risk of developing morbidities associated with systemic steroid exposure.

The cost of OCS-related adverse events in the main scenario was derived by combining the cost of each event with the relative rate. Annual costs per patient related to OCS-related adverse events in non-asthma control, mild/moderate, and severe asthma groups resulted equal to €1065,27, €1350,96 and €1957,50 respectively, [Table 4](#tbl4){ref-type="table"}.

Compared to the non-asthma control cohort, the annual per patient cost related to OCS-related adverse events resulted about €892 and €285 higher in severe asthma and moderate/mild cohort respectively. Annual per patient cost difference between asthmatic groups was about €606 (see [Table 5](#tbl5){ref-type="table"}).Table 5Cost per patient related to comorbidities.Table 5ComorbidityNon-asthma controlModerate asthmaSevere asthmaType II diabetes€ 83,49€ 97,40€ 139,15Obesity (BMI \>30)€ 404,30€ 615,24€ 738,29Osteopenia€ 18,81€ 18,81€ 94,03Osteoporosis€ 31,13€ 41,51€ 166,05Fracture€ 79,40€ 59,55€ 99,25Dyspeptic disorders€ 230,04€ 325,89€ 623,03Glaucoma€ 31,53€ 31,53€ 42,04Cataract€ 42,04€ 52,55€ 94,60Cardiovascular disease€ 146,78€ 146,78€ 209,68Hypertension€ 240,84€ 279,38€ 327,54Psychiatric disorders€ 485,45€ 601,96€ 737,89Hypercholesterolaemia€ 47,13€ 59,98€ 64,26Sleep disorder€ 28,18€ 35,22€ 56,36Chronic kidney disease€ 261,41€ 336,10€ 522,83Total for 2-year analysis€ 2130.54€ 2701.91€ 3915.00Annual total cost1065.27 €1350.96 €1957.50 €

We extended the total annual cost for patient to the estimated severe asthma Italian population in treatment with OCS (n = 123,988) in order to obtain budget impact results: ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Annual cost related to oral corticosteroids-related adverse events in target population.Fig. 1

Comparing severe asthma annual costs with those of non-asthmatic population, an incremental expenditure of about € 110.6 million was shown, which was reduced to about € 75.2 compared to the moderate asthma. The difference between the population with moderate asthma compared to the non-asthmatic control was lower, reaching approximately €35.4 million ([Fig. 2](#fig2){ref-type="fig"}).Fig. 2Incremental cost scenario: cost related to oral corticosteroids-related adverse events in main analysis.

Subgroup analysis {#sec3.1}
-----------------

We evaluated the economic impact of the five most common OCS-adverse event, considering cost of illness studies available, in order to adopt an alternative method to DRG tariffs. The results are shown in [Fig. 3](#fig3){ref-type="fig"}. Specifically, the subgroup analysis allowed to highlight the economic impact exercised by type 2 diabetes, obesity, fractures, glaucoma and chronic kidney disease according to literature data. These five diseases alone were able to result in a total annual cost equal to €92.7 million in the population with severe asthma, involving an additional expenditure of approximately €41.5 million compared to control and €26.3 million compared to populations with moderate asthma ([Fig. 3](#fig3){ref-type="fig"}).Fig. 3Incremental cost scenario: cost related to oral corticosteroids-related adverse events in sub-analysis scenario.

Sensibility analysis {#sec3.2}
--------------------

In [Table 6](#tbl6){ref-type="table"} sensibility analysis results are shown.Table 6Sensibility analysis results.Table 6Main scenarioAnnual costIncremental costNon-asthma control€ 2131Severe asthma vs control€ 1784Moderate asthma€ 2702Severe asthma vs moderate€ 1213Severe asthma€ 3915Moderate asthma vs control€ 571Lombardia DRG costAnnual costIncremental costNon-asthma control€ 2441Severe asthma vs control€ 2263Moderate asthma€ 3099Severe asthma vs moderate€ 1605Severe asthma€ 4704Moderate asthma vs control€ 658DRG National tarriffs -20%Annual costIncremental costNon-asthma control€ 1704Severe asthma vs control€ 1428Moderate asthma€ 2162Severe asthma vs moderate€ 970Severe asthma€ 3132Moderate asthma vs control€ 457DRG National tarriffs +20%Annual costIncremental costNon-asthma control€ 2557Severe asthma vs control€ 2141Moderate asthma€ 3242Severe asthma vs moderate€ 1456Severe asthma€ 4698Moderate asthma vs control€ 686Prevalence rates -20%Annual costIncremental costNon-asthma control€ 1704Severe asthma vs control€ 1428Moderate asthma€ 2162Severe asthma vs moderate€ 970Severe asthma€ 3132Moderate asthma vs control€ 457Prevalence rates +20%Annual costIncremental costNon-asthma control€ 2557Severe asthma vs control€ 2141Moderate asthma€ 3242Severe asthma vs moderate€ 1456Severe asthma€ 4698Moderate asthma vs control€ 686

Using a deterministic sensitivity analysis (DSA), we investigated the sensitivity of the results from the model-based analysis to variations in cost of adverse events and prevalence rates of OCS-related adverse events, which are among the main input parameters used for the cost analysis. Specifically, varying these values by ±20%, no significant changes in the final results were reported, highlighting the robustness of the budget impact analysis result.

Discussion {#sec4}
==========

This budget impact analysis highlighted the significant economic burden of morbidity related to systemic corticosteroid exposure in severe asthma population from the Italian NHS perspective. Our analysis, starting from national demographic data, asthma epidemiological data and adopting first published extractions from the Severe Asthma Network in Italy (SANI) registry, identified the proportion of subjects potentially at risk of developing comorbidities associated with systemic steroid exposure and showed that co-morbid costs were greater in the severe asthma patients, subjected to treatment with high-medium oral corticosteroids, compared to moderate and non-asthmatic cohort.

Total annual cost per patient associated with comorbid conditions due to OCS use was estimated at €1957.50 for the severe asthma cohort, almost twice that non-asthmatic population, and more than 30% compared to the population with moderate asthma, (€1350.96). Annual cost per patient difference between severe and moderate groups was about €606. The cost was determined by the higher prevalence of OCS-related adverse events in severe asthma cohort, considering the correlation between regular intensive use of systemic steroid therapy and disease onset and consequent impact on cost. For the analysis we considered the co-morbidities most frequently associated with the use of corticosteroids taken from the Sweeney\'s study,[@bib19] which provided events prevalence data for the three cohorts in analysis.

Applying the cost per patient to the target population identified for Italy, the budget impact model estimated a total annual cost related to OCS-related adverse events of €242.7 million for severe asthmatics. In respect with non-asthmatic and moderate asthma population, an incremental expenditure of about € 110.6 million and €75.2, respectively, was shown. The micro-costing analysis conducted based on cost of illness studies available for Italy, allowed to evaluate the impact of a subset of diseases, offering an alternative economic evaluation method. Five OCS-related adverse events alone, type 2 diabetes, obesity, fractures, glaucoma and chronic kidney disease, resulted in a total annual cost equal to €92.7 million in the population with severe asthma. The robustness of main analysis was confirmed by sensitivity analysis. Moreover, given regional tariffs variability in Italy for acute care hospital services, in order to provide an example of regional valorisation, we adopted DRG tariffs used in Lombardy region, recognized higher than the national average.

According to international guidelines, oral corticosteroid (OCS) treatment in asthma should be reserved to acute exacerbations (with short course of therapy) or to those severe patients remaining clinically uncontrolled or at high risk for future loss of control, despite high dose of inhaled corticosteroids (ICS) plus another controller, such as long-term beta2-agonists (better if combined, in a single inhaler, with ICS), leukotriene-receptor antagonists (LTRA), tiotropium or theophylline.[@bib36] Anyway, even in case of severe asthma, the suggestion is to use low-dose of OCS as a second-choice treatment after having considered the possibility to use biologic agents such as anti-IgE or anti-IL5 monoclonal antibodies.[@bib36]

However, the first published real-life data raised by the SANI registry[@bib29] put in evidence a dramatic situation in which more than 60% of severe asthmatics are chronically taking OCS, being therefore at high risk of OCS-related adverse events. An even more dramatic picture emerged from the updated SANI registry data recently published and showing a prevalence of OCS users higher than 64% of all severe asthmatics.[@bib37] A similar picture has been described by Zeiger et al. in a recent retrospective observational cohort study of adults with persistent asthma: they found an overall prevalence of OCS-treated patients of about 8.2% which corresponded to the great majority of those with severe asthma stigmata.[@bib18]

Putting these real-life data together with the evidence that severe asthmatics are often affected by comorbidities requiring chronic use of topical (i.e.: intranasal) or systemic corticosteroids,[@bib19] it is easily predictable that these patients have a high probability to develop corticosteroid adverse events. This risk is further increased considering that also chronic use of high (often higher than suggested) dose of ICS has been associated with significant adverse events.[@bib23], [@bib38]

The high prevalence of OCS use and the well-known impact of these drugs on the onset of complications, from minor events to potentially life-threating conditions, in any case impacting patient\'s quality of life, have led to develop studies aimed at considering even their economic impact. Behind the low acquisition cost of these drugs, the cost associated with OCS-induced morbidity hides, representing a shadow cost not to be missed. The significance of this topic, also considering current OCS-sparing effect therapies availability, is demonstrated by various published studies that, in line with ours, paid attention to the economic burden of adverse events associated with drugs exposure.

Some reviews analysed the corticosteroids effect in term of adverse events and cost considering the effects on more pathologies or focusing on the asthma only.[@bib25], [@bib39] Findings from these studies showed systemic corticosteroids are a common cause of comorbidities and the costs of managing these events can be substantial. Therefore, clinical and economic burden of systemic related adverse events highlights the need for OCS sparing therapies to be adopted.

Focusing on asthma, some studies have been carried out to evaluate the risk of systemic corticosteroids complications by steroid exposure and quantify the associated health care costs and resource use in patients with severe asthma requiring a regular therapy.

Lefebvre et al. performed a longitudinal, open-cohort, observational study using health insurance claims data; the adjusted risk of systemic corticosteroids related complications for patients with medium and high exposure compared with patients with low exposure and quantify the resulting health care resource use and costs were estimated: patients with medium and high systemic corticosteroids exposure had significantly higher risks of steroids related complications versus those with low exposure.[@bib40]

Luskin *et al* with their cross-sectional, matched-cohort, retrospective study, using a commercial claims database, estimated the prevalence of possible oral corticosteroid (OCS)-related side effects and health care resource use and costs in patients with asthma.[@bib41] Adults with asthma diagnosis codes and evidence of asthma medication use were studied. Patients with high OCS use (≥30 days of OCS annually) with possible OCS-related adverse events were more likely to have office visits and hospitalizations than those without possible side effects. High OCS users with possible side effects had higher adjusted total annual mean health care costs (\$25,168) than those without such side effects (\$21,882).[@bib41]

Our study is consistent with the data reported in literature, highlighting the correlation between the severity of asthmatic disease, and the increase in costs related to systemic corticosteroid-induced morbidities: differences in costs were significant between patients with asthma differentiated by steroid exposure. Moreover, this article is the first data from Italian Registry of Severe Asthma (SANI) that shows economic impact of OCS-overuse. This result is in line with that emerged from Barry\'s *et al* study,[@bib27] that have prevalence rates of corticosteroid-induced morbidity in common with our, corresponding to the economic evaluation of the results from the Sweeney study.[@bib19] According to UK NHS, Barry\'s study aimed to estimate the additional healthcare costs associated with steroid induced morbidity by comparing three patients\' groups: those with severe asthma, moderate asthma and no asthma. Average healthcare costs per person per year range from £2603 - £4533 for the severe asthma cohort, to £978 - £2072 for the mild/moderate asthma cohort, to £560 - £1324 for the non-asthma control cohort, depending on different costing scenario considered.[@bib27]

The excess risk of complications associated with long-term maintenance OCS use and related cost was also estimated by Tilden *et al* for the Australian population;[@bib26] this study, in addiction, considered quality-adjusted life year (QALY) losses due to corticosteroids exposure, focusing on eight disease outcomes significantly impacting costs QALY burden: type II diabetes, myocardial infarction, glaucoma, cataract, ulcer, osteoporosis, infection, and stroke. Expected annual cost of maintenance OCS-related disease outcomes resulted \$598.32 per patient per year. Each patient treated with maintenance OCS also reported a QALY loss of 0.0367 per year of treatment. These effects are considered reversible once patients stop taking maintenance OCS.[@bib26]

Different strategies have been developed to reduce the use of the corticosteroid load in asthma,[@bib42] ranging from allergy immunotherapy (not suitable for uncontrolled asthmatics),[@bib43] to biologic agents used in severe patients, as omalizumab,[@bib44] mepolizumab,[@bib45] benralizumab[@bib46] and dupilumab.[@bib47] The biologic treatment of severe asthma, into the context of a more personalized approach to the patients,[@bib48] seems to be a safe and effective steroid-sparing therapy; biologic agents are generally quite expensive and this, with payer policies, is currently one of the main limitation of their use in clinical practice, even if real-life studies demonstrated that their correct use is globally cost-effectiveness.[@bib49], [@bib50], [@bib51] To this purpose, the big data coming from registries like SANI will provide the opportunity to monitor OCS sparing effect of biologic agents in a real-life setting. However, even considering the more long-lived biologic agent for severe asthma (omalizumab), there is the real-life evidence that still a large group of individuals who may benefit from this drug are not receiving it.[@bib52] In the very selected population of patients followed by tertiary reference centers for severe asthma in Italy, composed in 95% of cases of patients classified as GINA V step severity, the underuse of biologic agents is confirmed: only about 60% of those eligible to at least one biologic agent are receiving this kind of therapy.[@bib29]

Further studies are needed to investigate if a wider use biologic agent in severe asthmatics may be cost-effective also in terms of reduction of OCS-related adverse events costs.

Our study provides estimates of additional healthcare costs related to corticosteroid induced adverse events in severe asthma patients from the Italian NHS perspective, not analysed previously. Budget impact model results highlighted the relevant economic impact of OCS-related adverse events in severe asthma patients, subjected to regular exposure to corticosteroids, compared to not exposed. The availability of the first epidemiologic data from SANI registry allowed the definition of target population based on national real word data. The future extrapolation of additional data from SANI registry will support the development of a model populated with national data, providing an important tool for further analyses and greater robustness. Indeed, use of adverse events prevalence rates derived from a UK respiratory database (OPCRD)[@bib19] could be seen as a limit of our study. However, it was necessary, because there were no data available for Italy. To overcome the uncertainty of this data, together with that associated with the cost of adverse events, we conducted a sensitivity analysis. Economic evaluation was carried out adopting direct cost associated with corticosteroids related adverse events management, according to Italian NHS. Indirect costs were not considered despite their impact could be relevant due to effects of OCS-related adverse events on productivity and quality of life loss. Overall, the analysis conducted can be considered conservative, indeed the number of evaluable adverse events can be expanded and for economic evaluation we considered unique national tariffs, to achieve greater homogeneity, in a context of national variability.
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